Anglais

The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.

19 Formulaires  
  1. StudyEvent: SEV1
    1. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    2. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    3. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    9. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    10. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. Subject - Consent Information
    15. Subject - Sample Mapping (including mapping to Coriell IDs)
    16. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    17. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
pht000381.v2.p1
Description

pht000381.v2.p1

DUMMY ID NUMBER
Description

ID2

Type de données

string

STUDY VISIT NUMBER AT WHICH NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
Description

VISNO

Type de données

text

TAKEN AN NSAID (EXCEPT COX-2 INHIBITORS) IN LAST 10 YEARS FOR AT LEAST 5X/WEEK FOR AT LEAST 3 MONTHS (ALL PARTICIPANTS)
Description

NSAIDS

Type de données

text

LOW-DOSE BABY ASPIRIN (81MG) (ALL PARTICIPANTS)
Description

BABYASP

Type de données

text

LOW-DOSE BABY ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
Description

BABYPILS

Type de données

text

REGULAR STRENGTH ASPIRIN (ALL PARTICIPANTS)
Description

REGASP

Type de données

text

ANACIN (400MG) (ALL PARTICIPANTS)
Description

ANACIN

Type de données

text

ANACIN PILLS/DAY (ALL PARTICIPANTS)
Description

ANACNPIL

Type de données

text

BAYER/BUFFERIN/ECOTRIN (325 MG) (ALL PARTICIPANTS)
Description

BAYER

Type de données

text

BAYER/BUFFERIN/ECOTRIN PILLS/DAY (ALL PARTICIPANTS)
Description

BAYRPILS

Type de données

text

OTHER REGULAR-STRENGTH ASPIRIN (ALL PARTICIPANTS)
Description

OTHASP

Type de données

text

OTHER REGULAR-STRENGTH ASPIRIN NAME (ALL PARTICIPANTS)
Description

OTHASPSP

Type de données

string

OTHER REGULAR-STRENGTH ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
Description

OTHASPIL

Type de données

text

EXTRA/MAXIMUM STRENGTH ASPIRIN (500 MG) (ALL PARTICIPANTS)
Description

MAXIMUM

Type de données

text

EXTRA/MAXIMUM STRENGTH ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
Description

MAXPILS

Type de données

text

EXCEDRIN EXTRA STRENGTH/MIGRAINE (250 MG ASPIRIN; 250 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
Description

EXCEDRIN

Type de données

text

EXCEDRIN EXTRA STRENGTH/MIGRAINE PILLS/DAY (ALL PARTICIPANTS)
Description

EXCEDPIL

Type de données

text

VANQUISH (227 MG ASPIRIN; 194 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
Description

VANQUISH

Type de données

text

VANQUISH PILLS/DAY (ALL PARTICIPANTS)
Description

VANQPILS

Type de données

text

IBUPROFEN (200 MG) (ALL PARTICIPANTS)
Description

IBUPROF

Type de données

text

IBUPROFEN PILLS/DAY (ALL PARTICIPANTS)
Description

IBUPRPIL

Type de données

text

NAPROXEN (ALL PARTICIPANTS)
Description

NAPROXEN

Type de données

text

ALEVE (220 MG) (ALL PARTICIPANTS)
Description

ALEVE

Type de données

text

ALEVE PILLS/DAY (ALL PARTICIPANTS)
Description

ALEVEPIL

Type de données

text

ANAPROX DS (550 MG) (ALL PARTICIPANTS)
Description

ANAPROX

Type de données

text

ANAPROX DS PILLS/DAY (ALL PARTICIPANTS)
Description

ANAPRPIL

Type de données

text

NAPROSYN/NAPRELAN (375 MG) (ALL PARTICIPANTS)
Description

NAPRO375

Type de données

text

NAPROSYN/NAPRELAN (375 MG) PILLS/DAY (ALL PARTICIPANTS)
Description

NAP375PL

Type de données

text

NAPROSYN/NAPRELAN (500 MG) (ALL PARTICIPANTS)
Description

NAPRO500

Type de données

text

NAPROSYN/NAPRELAN (500MG) PILLS/DAY (ALL PARTICIPANTS)
Description

NAP500PL

Type de données

text

OTHER NAPROXEN (ALL PARTICIPANTS)
Description

OTHNAP

Type de données

text

OTHER NAPROXEN NAME (ALL PARTICIPANTS)
Description

OTHNAPSP

Type de données

string

OTHER NAPROXEN PILLS/DAY (ALL PARTICIPANTS)
Description

OTHNAPPL

Type de données

text

PIROXICAM/FELDENE (10 MG) (ALL PARTICIPANTS)
Description

PIROX10

Type de données

text

PIROXICAM/FELDENE (10 MG) PILLS/DAY (ALL PARTICIPANTS)
Description

PIRX10PL

Type de données

text

PIROXICAM/FELDENE (20 MG) (ALL PARTICIPANTS)
Description

PIROX20

Type de données

text

PIROXICAM/FELDENE (20 MG) PILLS/DAY (ALL PARTICIPANTS)
Description

PIRX20PL

Type de données

text

ACETAMINOPHEN (PILLS/DAY) (ALL PARTICIPANTS)
Description

ACETAPIL

Type de données

text

OTHER NSAID (ALL PARTICIPANTS)
Description

OTHNSAID

Type de données

text

OTHER NSAID NAME (ALL PARTICIPANTS)
Description

OTHNSASP

Type de données

string

OTHER NSAID PILLS/DAY (ALL PARTICIPANTS)
Description

OTHNSAPL

Type de données

text

HOW LONG ON NSAID AT LEAST 5 TIMES/WEEK (ALL PARTICIPANTS)
Description

HOWLONG

Type de données

text

ACETAMINOPHEN (500 MG) (ALL PARTICIPANTS)
Description

ACETAM

Type de données

text

YEARS FROM RANDOMIZATION TO DATE OF STUDY VISIT WHERE NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
Description

NSAIDSTIME

Type de données

float

Retour au début de la page

Similar models

The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.

19 Formulaires
  1. StudyEvent: SEV1
    1. The data table (n=142 variables) contains AMD and cataract phenotype information, medical history and socio-demographic information drawn from several data sets (e.g. enrollment_randomization, amdlensphenotype, followup), plus a unique patient identifier (ID2) for participants with a genetic specimen (to be found only in GENSPECPHENOTYPE and GENSPECFUNDUSLENS [pht000376] tables). Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Other disease information (e.g. diabetes, cancer, angina), medical information (e.g. BMI, blood pressure) and smoking status are also included annually throughout follow-up.
    2. The data table (n=12 variables) contains information about the occurrence of adverse events during the AREDS clinical trial, e.g. type of adverse event, severity, primary ICD9 code, outcome, potential relationship to study drug, timing, and treatment. Data were collected through the clinical trial and for the first 6 months of the natural history follow-up immediately after the clinical trial concluded. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    3. The data table (n=25 variables) contains detailed information about cataract phenotypes (n=23 variables) as well as final AMD phenotype (n=1 variable), and patient ID. Nuclear, cortical and posterior subcapsular opacity information is included for both eyes at baseline and end of study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    4. The data table (n=56 variables) contains information about AREDS participants' dietary intake of alcohol, amino acids, carbohydrates, fiber, poly- and monounsaturated fatty acids, proteins, vitamins and minerals. Participants' glycemic index and glycemic load are also included. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    5. The data table (n=102 variables) contains AREDS treatment assignment, basic socio-demographic characteristics and baseline medical history for AREDS participants. Medical history information includes eye disease information such as AMD Category, visual acuity, and past ophthalmic treatments (e.g. cataract surgery, laser treatment), as well as information about the presence/absence of other diseases (e.g. angina, arthritis, cancer, diabetes, high blood pressure), use of prescribed drugs for disease management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), intake of vitamins and minerals, and smoking history. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    6. The data table (n=83 variables) contains information obtained at follow-up visits during the AREDS clinical trial (every six months following randomization), annually in person during the natural history follow-up, and via phone between annual in-person visits. Variables include information about AREDS participants' ophthalmic medical history (e.g. cataract or other eye surgery, laser treatment for AMD, retinal repair, capsulotomy, presence/absence of lens, glaucoma, and visual acuity) and general medical information, including new diagnoses of cancer, heart disease, stroke, and peripheral vascular disease, disease history of angina and high blood pressure, current disease status of diabetes, arthritis, and gout, use of prescribed drugs for disease treatment or management (e.g. blood-thinning medications, digoxin, thyroid hormones, insulin), use of over-the-counter drugs (e.g. NSAIDs, antacids), and smoking behavior. For version 3 release of the study, visual acuity data of the right eye have been added for odd-numbered visits. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    7. The data table (n=49 variables) contains information from AREDS participants' fundus photographs, including presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy. In addition, information on photocoagulation (PC) treatment for AMD SRNV is included, as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    8. The data table (n=62) contains information only for AREDS participants who have a genetic specimen. A unique patient identifier (ID2 field) for these participants (to be found only in GENSPECPHENOTYPE [pht000001.v2.p1] and GENSPECFUNDUSLENS data tables) is included instead of the patient identifier used for data tables with all participants (ID field). Information about fundus and lens characteristics are included as follows - fundus: presence, type, and extent of drusen, presence/extent of RPE depigmentation, SSR (serous sensory retinal) detachments, subretinal hemorrhages, subretinal fibrosis, and geographic atrophy; lens: degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. In addition, information on photocoagulation (PC) treatment for AMD is included as well as AMD Severity Scale Scores and AMD Simple Scale Scores calculated from the fundus data.
    9. The data table (n=6 variables) contains information about AREDS participant hospitalizations (e.g. reason, time from randomization, duration, primary ICD9 code) during the entire study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    10. The data table (n=21 variables) contains information from AREDS participants' lens photographs, including degree of nuclear sclerosis, cortical and posterior subcapsular opacities, and iris pigmentation. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    11. The data table (n=7 variables) contains information about AREDS participant deaths (e.g. cause, time from randomization) during the entire study. A search using the National Death Index (NDI) yielded additional deaths not identified during the study. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    12. The data table (n=44 variables) contains information about AREDS participants' use (e.g. type, frequency, dose, duration) of non-steroidal anti-inflammatory drugs (e.g. aspirin, ibuprofen, acetaminophen, naproxen). Data were collected at in-clinic visits starting in October 2004. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    13. The data table (n=16 variables) contains information about AREDS participants' general vision status (e.g. general vision score, ocular pain score, VFQ overall score), and its effect on participants' behavior (e.g. near and distant activities, social activities, driving, mental health score) as obtained through the VFQ-25 questionnaire. Note: In version 3, the ID has been replaced by ID2 identifier for all subjects.
    14. Subject - Consent Information
    15. Subject - Sample Mapping (including mapping to Coriell IDs)
    16. The data table (n=2 variables) contains information on subjects' annual exposure to sunlight (hours; April through September).
    17. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    18. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
    19. This dataset provides refractive error values obtained from control subjects of the AREDS study (phs000001.v3.p1) and represents a substudy of AREDS ; data of n=7 new variables are provided in addition to basic sociodemographic data. Subject - consent and subject - sample mapping information is available through phs000001.v3.p1.
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
pht000381.v2.p1
ID2
Item
DUMMY ID NUMBER
string
Item
STUDY VISIT NUMBER AT WHICH NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
text
VISNO
Code List
STUDY VISIT NUMBER AT WHICH NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
CL Item
Baseline visit (00)
CL Item
0.5-year (01)
CL Item
1-year (02)
CL Item
1.5-years (03)
CL Item
2-years (04)
CL Item
2.5-years (05)
CL Item
3-years (06)
CL Item
3.5-years (07)
CL Item
4-years (08)
CL Item
4.5-years (09)
CL Item
5-years (10)
CL Item
5.5-years (11)
CL Item
6-years (12)
CL Item
6.5-years (13)
CL Item
7-years (14)
CL Item
7.5-years (15)
CL Item
8-years (16)
CL Item
8.5-years (17)
CL Item
9-years (18)
CL Item
9.5-years (19)
CL Item
10-years (20)
CL Item
10.5-years (21)
CL Item
11-years (22)
CL Item
11.5-years (23)
CL Item
12-years (24)
CL Item
12.5-years (25)
CL Item
13-years (26)
Item
TAKEN AN NSAID (EXCEPT COX-2 INHIBITORS) IN LAST 10 YEARS FOR AT LEAST 5X/WEEK FOR AT LEAST 3 MONTHS (ALL PARTICIPANTS)
text
NSAIDS
Code List
TAKEN AN NSAID (EXCEPT COX-2 INHIBITORS) IN LAST 10 YEARS FOR AT LEAST 5X/WEEK FOR AT LEAST 3 MONTHS (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
LOW-DOSE BABY ASPIRIN (81MG) (ALL PARTICIPANTS)
text
BABYASP
Code List
LOW-DOSE BABY ASPIRIN (81MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
BABYPILS
Item
LOW-DOSE BABY ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
text
Item
REGULAR STRENGTH ASPIRIN (ALL PARTICIPANTS)
text
REGASP
Code List
REGULAR STRENGTH ASPIRIN (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
ANACIN (400MG) (ALL PARTICIPANTS)
text
ANACIN
Code List
ANACIN (400MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
ANACNPIL
Item
ANACIN PILLS/DAY (ALL PARTICIPANTS)
text
Item
BAYER/BUFFERIN/ECOTRIN (325 MG) (ALL PARTICIPANTS)
text
BAYER
Code List
BAYER/BUFFERIN/ECOTRIN (325 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
BAYRPILS
Item
BAYER/BUFFERIN/ECOTRIN PILLS/DAY (ALL PARTICIPANTS)
text
Item
OTHER REGULAR-STRENGTH ASPIRIN (ALL PARTICIPANTS)
text
OTHASP
Code List
OTHER REGULAR-STRENGTH ASPIRIN (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
OTHASPSP
Item
OTHER REGULAR-STRENGTH ASPIRIN NAME (ALL PARTICIPANTS)
string
OTHASPIL
Item
OTHER REGULAR-STRENGTH ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
text
Item
EXTRA/MAXIMUM STRENGTH ASPIRIN (500 MG) (ALL PARTICIPANTS)
text
MAXIMUM
Code List
EXTRA/MAXIMUM STRENGTH ASPIRIN (500 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
MAXPILS
Item
EXTRA/MAXIMUM STRENGTH ASPIRIN PILLS/DAY (ALL PARTICIPANTS)
text
Item
EXCEDRIN EXTRA STRENGTH/MIGRAINE (250 MG ASPIRIN; 250 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
text
EXCEDRIN
Code List
EXCEDRIN EXTRA STRENGTH/MIGRAINE (250 MG ASPIRIN; 250 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
EXCEDPIL
Item
EXCEDRIN EXTRA STRENGTH/MIGRAINE PILLS/DAY (ALL PARTICIPANTS)
text
Item
VANQUISH (227 MG ASPIRIN; 194 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
text
VANQUISH
Code List
VANQUISH (227 MG ASPIRIN; 194 MG ACETAMINOPHEN) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
VANQPILS
Item
VANQUISH PILLS/DAY (ALL PARTICIPANTS)
text
Item
IBUPROFEN (200 MG) (ALL PARTICIPANTS)
text
IBUPROF
Code List
IBUPROFEN (200 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
IBUPRPIL
Item
IBUPROFEN PILLS/DAY (ALL PARTICIPANTS)
text
Item
NAPROXEN (ALL PARTICIPANTS)
text
NAPROXEN
Code List
NAPROXEN (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
Item
ALEVE (220 MG) (ALL PARTICIPANTS)
text
ALEVE
Code List
ALEVE (220 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
ALEVEPIL
Item
ALEVE PILLS/DAY (ALL PARTICIPANTS)
text
Item
ANAPROX DS (550 MG) (ALL PARTICIPANTS)
text
ANAPROX
Code List
ANAPROX DS (550 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
ANAPRPIL
Item
ANAPROX DS PILLS/DAY (ALL PARTICIPANTS)
text
Item
NAPROSYN/NAPRELAN (375 MG) (ALL PARTICIPANTS)
text
NAPRO375
Code List
NAPROSYN/NAPRELAN (375 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
NAP375PL
Item
NAPROSYN/NAPRELAN (375 MG) PILLS/DAY (ALL PARTICIPANTS)
text
Item
NAPROSYN/NAPRELAN (500 MG) (ALL PARTICIPANTS)
text
NAPRO500
Code List
NAPROSYN/NAPRELAN (500 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
NAP500PL
Item
NAPROSYN/NAPRELAN (500MG) PILLS/DAY (ALL PARTICIPANTS)
text
Item
OTHER NAPROXEN (ALL PARTICIPANTS)
text
OTHNAP
Code List
OTHER NAPROXEN (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
OTHNAPSP
Item
OTHER NAPROXEN NAME (ALL PARTICIPANTS)
string
OTHNAPPL
Item
OTHER NAPROXEN PILLS/DAY (ALL PARTICIPANTS)
text
Item
PIROXICAM/FELDENE (10 MG) (ALL PARTICIPANTS)
text
PIROX10
Code List
PIROXICAM/FELDENE (10 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
PIRX10PL
Item
PIROXICAM/FELDENE (10 MG) PILLS/DAY (ALL PARTICIPANTS)
text
Item
PIROXICAM/FELDENE (20 MG) (ALL PARTICIPANTS)
text
PIROX20
Code List
PIROXICAM/FELDENE (20 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
PIRX20PL
Item
PIROXICAM/FELDENE (20 MG) PILLS/DAY (ALL PARTICIPANTS)
text
ACETAPIL
Item
ACETAMINOPHEN (PILLS/DAY) (ALL PARTICIPANTS)
text
Item
OTHER NSAID (ALL PARTICIPANTS)
text
OTHNSAID
Code List
OTHER NSAID (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
OTHNSASP
Item
OTHER NSAID NAME (ALL PARTICIPANTS)
string
OTHNSAPL
Item
OTHER NSAID PILLS/DAY (ALL PARTICIPANTS)
text
Item
HOW LONG ON NSAID AT LEAST 5 TIMES/WEEK (ALL PARTICIPANTS)
text
HOWLONG
Code List
HOW LONG ON NSAID AT LEAST 5 TIMES/WEEK (ALL PARTICIPANTS)
CL Item
Less than 1 year (1)
CL Item
More or equal to 1 and less than 3 years (2)
CL Item
More or equal to 3 and less than 7 years (3)
CL Item
More or equal to 7 years (4)
Item
ACETAMINOPHEN (500 MG) (ALL PARTICIPANTS)
text
ACETAM
Code List
ACETAMINOPHEN (500 MG) (ALL PARTICIPANTS)
CL Item
No (N)
CL Item
Yes (Y)
NSAIDSTIME
Item
YEARS FROM RANDOMIZATION TO DATE OF STUDY VISIT WHERE NSAID DATA WAS COLLECTED (ALL PARTICIPANTS)
float
Retour au début de la page